A Phase III Clinical Study of Tislelizumab Combined With GX Regimen Versus Tislelizumab Combined With GP Regimen in the First-line Treatment of Recurrence or Metastasis (R/M) Nasopharyngeal Carcinoma (NPC)

NCT06177301 Phase 3 RECRUITING

The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.

Details

Lead sponsor	Fudan University
Phase	Phase 3
Status	RECRUITING
Enrolment	266
Start date	2023-12-01
Completion	2027-12

Conditions

• Nasopharyngeal Carcinoma

Interventions

• Tislelizumab combined with GX
• Tislelizumab combined with GP

Primary outcomes

• To compare the progression-free survival of tislelizumab combined with GX regimen and tislelizumab combined with GP regimen based on the ITT analysis set evaluated by the researchers according to RECIST v1.1. — up to approximately 3 years
  Time from the date of enrollment to of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.

Countries

China